Hemab Therapeutics (COAG) vs Novavax (NVAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Novavax is the larger company by market cap ($1.82 billion vs $1.44 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COAG | NVAX |
|---|---|---|
| Share price | $30.89 | $11.01 |
| Market cap | $1.44B | $1.82B |
| 1-day change | +7.63% | -1.87% |
| YTD return | — | +63.84% |
| 1-year return | — | +23.71% |
| 5-year return | — | -93.20% |
| EPS (TTM) | $-4.33 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.12B |
| Revenue growth (YoY) | — | +64.69% |
| Net income (latest FY) | — | $440.30M |
| Gross margin | — | 93.50% |
| Operating margin | — | 40.30% |
| Net margin | — | 39.19% |
| 52-week high | $55.42 | $13.39 |
| 52-week low | $23.00 | $6.20 |
| Distance from 52-week high | -44.26% | -17.77% |
| Analyst consensus | none | buy |
| Avg. price target upside | +98.12% | +27.16% |
| Average volume | 458.71K | 5.21M |
| Shares outstanding | 46.71M | 164.95M |
| Employees | 59 | 749 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Hemab Therapeutics
COAG stock →Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 59 employees
About Novavax
NVAX stock →Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees
COAG vs NVAX FAQ
Which is bigger, Hemab Therapeutics or Novavax?
Novavax (NVAX) is larger, with a market capitalization of $1.82B compared with $1.44B for Hemab Therapeutics (COAG).
Are Hemab Therapeutics and Novavax in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.